Posted: 2nd May 2025
VivaZome Therapeutics Pty Ltd (“VivaZome”) have unveiled promising results at an international conference from their latest research on Traumatic Brain Injury (TBI) treatment. The findings, presented by Chief Scientific Officer Professor David Haylock at the International Society of Extracellular Vesicles (ISEV) conference in Vienna, Austria, highlighted the efficacy of VivaZome’s proprietary extracellular vesicles (EVs) in animal models of TBI.
The research, conducted in collaboration with the Centre for Advanced Imaging and the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland (UQ), demonstrated significant improvements in motor function, exploratory behavior, and balance in treated animals just 24 hours post-injury. Additionally, the data suggested a potential reduction in susceptibility to post-traumatic epilepsy (PTE), a debilitating condition affecting 1 in 50 TBI sufferers.
Professor Haylock emphasized the importance of these findings, stating, “Our EVs have shown a remarkable ability to dampen the initial inflammatory response, promoting functional recovery. This aligns with our previous demonstrations of the anti-inflammatory properties of our EVs in vitro and in other in vivo models.”
VivaZome’s CEO and Managing Director, Ms. Xenia Sango, expressed optimism about the future of TBI treatment, noting, “With over 700,000 Australians affected by brain injury, these results represent a significant step forward. We are committed to advancing our preclinical studies and moving towards clinical trials.”
Emeritus Professor David Reutens, Director of the Centre for Advanced Imaging at UQ, praised the collaboration, stating, “The promising results from our models of TBI highlight the potential for VivaZome’s EVs to transform patient care in brain injury and epilepsy.”
The results are a promising update for sufferers of TBI, which is described as a “silent epidemic” that contributes to worldwide death and disability more than any other traumatic insult.
The VivaZome poster “VivaZome Proprietary Human Cell-Derived Extracellular Vesicles Enhance Recovery AfterModerate Traumatic Brain Injury in a Preclinical Model” is available here.
